CFM
ZNTL icon

Catalyst Funds Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Catalyst Funds Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,700
Closed -$39.1K – 917
2026
Q1 		$39.1K Buy
+16,700
New +$43.1K 0.01% 555
2025
Q4 		– Sell
-51,400
Closed -$77.6K – 588
2025
Q3 		$77.6K Buy
51,400
+24,600
+92% +$36.9K 0.01% 468
2025
Q2 		$31.1K Buy
+26,800
New +$35.3K 0.01% 402
2024
Q3 		– Sell
-3,500
Closed -$14.3K – 1642
2024
Q2 		$14.3K Sell
3,500
-5,800
-62% -$64.8K ﹤0.01% 799
2024
Q1 		$147K Buy
+9,300
New +$128K 0.04% 319

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Catalyst Funds Management's ZNTL Position: Q2 2026 in Review

Catalyst Funds Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 16,700 shares — an estimated $39.1K sold.

Catalyst Funds Management first reported a position in ZNTL in Q1 2024 and held it in 5 quarters. The position peaked at $147K in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Catalyst Funds Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 16,700 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $39.1K.
  • Catalyst Funds Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Catalyst Funds Management's Zentalis Pharmaceuticals position peaked at $147K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.